Navigating A Transition Year: Five Takeaways From Pfizer’s Q1 Call

Pfizer’s management team addressed topics ranging from COVID-19 revenues to Medicare’s drug negotiation program and new product launches.

Pfizer reported first quarter financial results • Source: Shutterstock

Pfizer Inc. is continuing in a transition phase as it integrates the Seagen oncology business, right-sizes the COVID-19 business and builds commercial momentum behind newer drugs and vaccines across a wide array of therapeutic areas. It’s an important year for Pfizer to rebuild trust with investors after a disappointing 2023, when the company missed its financial forecast and had to reset expectations late in the year and implement cost cuts.

Key Takeaways
  • Pfizer reported a 20% first quarter revenue decline driven by lower COVID-19 sales, but sales grew 11% operationally excluding the vaccine Comirnaty and antiviral Paxlovid.

“We know credibility is extremely important for us,” CEO Albert Bourla told investors during the company’s first quarter sales and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Earnings

Loss Of Exclusivity Product Launches To Fuel Aurobindo’s FY26 Europe Growth

 
• By 

Aurobindo is banking on launches of loss of exclusivity products and biosimilars to fuel sales in Europe as it awaits a US announcement on tariffs and predicts high single-digit growth overall during FY26 for now

Korea Q1 Roundup: Mixed Earnings, Gearing For Possible US Tariffs

 
• By 

South Korean biopharma companies report a mostly solid first quarter, marked by US growth for original drugs, with several also making preparations for possible US pharma tariffs.

Sun On Leqselvi US Launch Ahead, MFN Pricing And Pipeline Changes

 

Sun readies US debut of Leqselvi for alopecia areata, while PD-L1 inhibitor Unloxcyt is in the line up once the Checkpoint Therapeutics deal is completed. Management also discusses limited clarity on President Trump’s most favored nation pricing push, pipeline tweaks and M&A outlook.

Stock Watch: Q1 Sales Trends And Forex Muddle Pharma Outlook

 
• By 

Pharma firms tended to downplay first-quarter trends in full-year guidance. However, raised guidance seems fragile amid ongoing foreign exchange effects and Medicare Part D redesign pressures.

More from Business

Finance Watch: Is Six The Magic Number? May Sees Half Dozen VC Mega-Rounds

 
• By 

Private Company Edition: Six biopharma companies raised venture capital rounds totaling $100m or more in May, matching the number of mega-rounds in April and March. Among other recent financings, Syndeio launched with $90m and SpyGlass raised a $75m series D round.

Bayer Boosted By Third FDA Approval For Nubeqa

 
• By 

US green light will further expand sales of the prostate cancer blockbuster.

Kymera STAT6 Data Set The Bar For ‘Dupixent-In-A-Pill’ Race

 

Kymera will move KT-621 into Phase II trials later this year based on compelling data in healthy volunteers, validating the company’s protein-degradation platform.